Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain

Bausch + Lomb (BLCO) reported Phase 2 results for BL1332, a topical TRPV1 antagonist for post-surgical ocular pain. While the primary endpoint at 24 hours was not met, both doses showed numerically greater pain relief than the vehicle. Exploratory analyses indicated faster corneal healing. The company plans to discuss findings with the FDA and potentially plan Phase 3 trials.

Original reporting
Published Nov 19, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain — source image
Decision brief

The 30-second read

$BLCONeutralMed
01

Why it matters

The key trading question is whether the missed primary endpoint meaningfully undermines the program or whether the consistent directional improvements and healing signals justify Phase 3 planning. The company’s stated intent to discuss study design and endpoints with FDA suggests an active mitigation path.

02

Market read

A Phase 2 clinical readout with a missed primary endpoint but supportive secondary and exploratory signals can shift probability-weighting for Phase 3 success and near-term pipeline valuation.

03

What to watch

The article provides limited detail on effect size consistency, multiplicity adjustments, and how SPID relates to patient-relevant outcomes. Traders may discount the nominal secondary significance and focus on endpoint redesign feasibility with FDA.

Relevance 7/10Novelty 6/10Timing: after-hours today, ahead of the 5 p.m. ET R&D leadership call

Background

BL1332 is a first-in-class topical TRPV1 antagonist being studied for ocular surface pain after PRK surgery; this is a Phase 2 topline readout with vehicle control.

Company-level read

Ticker impact

$BLCONeutralMedium confidence
Context

Bausch + Lomb reported Phase 2 topline results for BL1332, including failure to meet the 24-hour primary SPID endpoint and FDA discussion plans.

Expected impact

Shares may face near-term skepticism due to the missed primary endpoint, partially offset by supportive exploratory and secondary signals plus stated FDA Phase 3 planning.

Evidence & confidence

The article explicitly states the primary endpoint at 24 hours was not met, while also highlighting numerically better pain relief across analyses, nominal significance in a secondary window, and faster corneal healing signals. That combination typically reduces conviction for immediate re-rating but supports continued development optionality.

Market effects

Adds another data point for ocular pain/TRPV1 antagonist development risk, potentially influencing sentiment around ophthalmic pain pipeline programs.

Limited direct regional impact; clinical-trial read-through is mostly US-listed biotech/healthcare sentiment.

Moderate global relevance for ophthalmology R&D investors, but not a broad macro or sector-wide catalyst.

Counterpoint

The primary endpoint miss may be less damaging if the exploratory complete pain relief and corneal healing signals are clinically meaningful and can be translated into a revised Phase 3 endpoint strategy with FDA.

Key entities

  • Bausch + Lomb Corporation

    Reported Phase 2 topline results for BL1332 in post-PRK ocular pain and outlined next steps with FDA, including potential Phase 3 planning.

  • BL1332

    Topical TRPV1 antagonist evaluated at 0.30% and 0.15% versus vehicle in a randomized Phase 2 PRK pain study.

  • U.S. Food and Drug Administration (FDA)

    Will be engaged to align on future development, including potential Phase 3 planning and endpoint/study design adjustments.

Related articles

$BLCOMedAI 8/10

Bausch + Lomb (BLCO) BL1332 Misses Phase 2 Primary Endpoint

Bausch + Lomb's (BLCO) Phase 2 study for BL1332 missed its primary endpoint, showing no statistically significant improvement over the vehicle. The LS mean differences were -11.5 and -9.0, favoring BL1332 but not reaching significance. A 0.30% dose showed nominal significance at six hours for a secondary endpoint, with adverse event rates reported but no serious events.

$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

$BLCOHighAI 8/10

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.

$BLCOMed

Bausch + Lomb: Q3 Earnings Snapshot

Bausch + Lomb (BLCO) reported Q3 net income of $32M, or 9 cents per share, beating estimates. Adjusted EPS was 34 cents. Revenue was $1.38B, also topping forecasts. The company expects full-year revenue of $5.45B-$5.55B. Shares are up 14% YTD and 26% over 12 months.